BAL, has been smashed down around 60% from recent high, punished for the delay of SAMR approval.
However, BAL expects 2018 annual revenue to be around $312m - $324m with EBITDA of 21-23%.
BAL's infant formula revenue for 2018 year would be around A$300m,
A2M's infant formula revenue for 2018 year would be around A$720m, EBITDA of 30%, with CFDA/SAMR approval.
A2M's market cap is Seven times of BAL's.
BAL does have organic certificate to apply for CNCA, also the source of organic powder is an issue.
